Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharming Group ( (PHAR) ) has issued an update.
On February 3, 2026, Pharming Group issued 2026 financial guidance and used its virtual Investor Day to spotlight its advancing rare disease pipeline, particularly two key clinical programs targeting primary immunodeficiencies (PIDs) with immune dysregulation and mitochondrial DNA‑driven mitochondrial disease. The company forecast total revenues of US$405 million to US$425 million for 2026, implying 8% to 13% growth driven mainly by strong momentum in Joenja and continued RUCONEST sales, against operating expenses of US$330 million to US$335 million largely reflecting increased R&D outlays for ongoing Phase II trials of leniolisib in broader PID and common variable immunodeficiency populations and the pivotal FALCON trial of the newly named mitochondrial disease candidate napazimone (KL1333), with key readouts expected in 2026 and 2027 that could strengthen Pharming’s position in the rare disease market and create significant long‑term value for stakeholders if clinical results are positive.
The most recent analyst rating on (PHAR) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
Pharming Group’s overall score is driven by strong technical indicators and a positive earnings call, which highlight growth and operational improvements. However, the high P/E ratio and low profitability metrics weigh down the score, indicating valuation concerns and profitability challenges.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company focused on rare, debilitating and life‑threatening diseases, commercializing and developing a portfolio of innovative small‑molecule and biologic therapies. Headquartered in Leiden, the Netherlands, the company markets products such as Joenja and RUCONEST and serves patients in more than 30 markets across North America, Europe, the Middle East, Africa and Asia-Pacific.
Average Trading Volume: 27,786
Technical Sentiment Signal: Buy
Current Market Cap: $1.42B
See more insights into PHAR stock on TipRanks’ Stock Analysis page.